NOV 09, 2020 9:13 AM PST

COVID-19 Vaccine by Pfizer More than 90% Effective

WRITTEN BY: Annie Lennon

A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from contracting COVID-19. 

For the study, researchers tested the vaccine on over 43,000 people across six countries: the US, Germany, Brazil, Argentina, South Africa, and Turkey. During the Phase 3 trial, volunteers either received the COVID-19 vaccine, administered in two shots around three weeks apart, or a placebo alternative such as a meningitis vaccine. Neither doctors nor patients knew which they had. 

So far, the results look positive. From an interim analysis of the first confirmed 94 cases of COVID-19 among those involved in the research, scientists found that fewer than 10% of infections- or around eight people- had received the vaccine. This means that over 90% of the cases were people who had received the placebo. 

Pfizer has said that the vaccine had an efficacy rate of more than 90% at seven days after the second dose, meaning that protection is achieved within 28 days of beginning the vaccination process. While the companies behind the vaccine aim to have it approved by the end of the month, they aim to be able to assess 164 confirmed cases of COVID-19 infection among trial participants before final results are published.

The vaccine itself is based on a new approach involving messenger RNA (mRNA). Unlike other vaccines that directly use the virus, this vaccine uses the virus's mRNA to cause cells in the body to produce proteins that resemble the virus. This then triggers an immune response that recognizes and attacks these proteins, which are theoretically summoned again if the virus enters the body. 

While the vaccine is deemed to be effective, the CEO of Pfizer, Dr Albert Bourla, said that it is still unknown how long protection from the vaccine will last. He added that it is likely that people will need periodical vaccinations to ensure immunity. Regardless, Bourla has said that Pfizer expects to produce 50 million vaccine doses by the end of this year and 1.3 billion next year. 

 

Sources: BBCCNNThe Guardian

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
DEC 28, 2020
Cannabis Sciences
Does Cannabis Affect Stress in Men and Women Differently?
DEC 28, 2020
Does Cannabis Affect Stress in Men and Women Differently?
Researchers from Washington State University have found that cannabis may blunt the stress response differently in males ...
DEC 28, 2020
Drug Discovery & Development
Anti-Diarrhea Drug Kills Aggressive Brain Cancer Cells
DEC 28, 2020
Anti-Diarrhea Drug Kills Aggressive Brain Cancer Cells
Glioblastoma is a very aggressive and lethal form of brain cancer that responds poorly to chemotherapy in children and a ...
JAN 20, 2021
Microbiology
Cannabis Compound Could Lead to New Class of Antibiotics
JAN 20, 2021
Cannabis Compound Could Lead to New Class of Antibiotics
For the first time, a synthetic version of a non-psychoactive molecule found in marijuana has been shown to kill pathoge ...
JAN 16, 2021
Drug Discovery & Development
Scientists Discover Contents of an Ancient Mayan Drug Containers
JAN 16, 2021
Scientists Discover Contents of an Ancient Mayan Drug Containers
Washington State University researchers found a non-tobacco plant in containers of an ancient Maya drug. "While it ...
JAN 28, 2021
Immunology
Killers With a Hit on the Spike
JAN 28, 2021
Killers With a Hit on the Spike
Natural killer cells, or NK cells, are specialized immune cells of the innate immune system. Their job revolves around e ...
FEB 16, 2021
Immunology
Hugs From Immune Cells Heal Muscle
FEB 16, 2021
Hugs From Immune Cells Heal Muscle
Australian researchers have discovered a regenerative factor produced by immune cells that drives the repair and regener ...
Loading Comments...